FDA Safety Cmte. Consumer Rep Levin Is Critic Of Speedy Drug Reviews
Executive Summary
FDA's Drug Safety & Risk Management Advisory Committee consumer representative Arthur Levin will likely urge closer scrutiny of the safety profile of non-breakthrough drugs during NDA reviews